TALWIN COMPOUND
LOE ApproachingNDAORALTABLET
Approved
Nov 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN COMPOUND is an oral tablet small-molecule analgesic approved in 1975, currently owned by Sanofi. The product mechanism of action and specific indications are not documented in available records, limiting clinical characterization.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal competitive pressure (30%), career opportunities are likely concentrated in managed decline or transition roles rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TALWIN COMPOUND is a legacy product with zero linked job openings, indicating minimal active hiring or team expansion. Working on this product offers limited career growth potential but may suit professionals managing mature/declining brands or transitioning portfolios.
Brand ManagerSales Representative
Worked on TALWIN COMPOUND at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.